RVNC Live signaler | Maksimer profitt med Getagraph.com

KJøP 107883 min ago

@ $5.59

Utstedt: 14 feb 2024 @ 19:54

Avkastning: -33.66%

Forrige signal: feb 14 - 15:30

Forrige signal: Selg

Avkastning: 3.36 %

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 18:57):

Stats
Dagens volum	1.98M
Gjennomsnittsvolum	1.84M
Markedsverdi	386.64M
EPS	$0 ( 2024-02-28 )
Neste inntjeningsdato	( $-0.660 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.970
ATR14	$0.0130 (0.35%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-16	Jordan Erica	Sell	2 392	Common Stock
2024-03-15	Sjuts Dustin S	Sell	2 967	Common Stock
2024-03-18	Sjuts Dustin S	Sell	9 211	Common Stock
2024-03-15	Moxie Dwight	Sell	3 269	Common Stock
2024-03-18	Moxie Dwight	Sell	8 125	Common Stock

INSIDER POWER
64.41
Last 97 transactions
Buy: 2 720 068 \| Sell: 629 333

Volum Korrelasjon

Lang: -0.06 (neutral)

Kort: -0.44 (neutral)

Signal:(55.002) Neutral

Revance Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner
SYKE	0.944
SPRB	0.923
BRACU	0.922
XLRN	0.921
PIRS	0.918
ATCX	0.918
MESA	0.915
VRME	0.915
JFIN	0.913
OVID	0.907

10 Mest negative korrelasjoner
AHPI	-0.934
TUEM	-0.902
VERA	-0.881
ARDS	-0.865
CYTO	-0.86
NAKD	-0.852
LCAP	-0.85
CFV	-0.844
JRJC	-0.843
APM	-0.837

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Revance Therapeutics Inc Korrelasjon - Valuta/Råvare

-0.42
( neutral )

-0.54
( weak negative )

0.00
( neutral )

0.33
( neutral )

0.45
( neutral )

Revance Therapeutics Inc Økonomi

Annual	2023
Omsetning:	$234.04M
Bruttogevinst:	$145.98M (62.38 %)
EPS:	$-3.83

FY	2023
Omsetning:	$234.04M
Bruttogevinst:	$145.98M (62.38 %)
EPS:	$-3.83

FY	2022
Omsetning:	$132.57M
Bruttogevinst:	$80.90M (61.03 %)
EPS:	$-4.90

FY	2021
Omsetning:	$77.80M
Bruttogevinst:	$54.39M (69.91 %)
EPS:	$-4.17

Financial Reports:

No articles found.

Revance Therapeutics Inc

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.